TABLE 2.

Individual participant demographic and clinical parameters.

Patient	Group	Sex	Age (years)	FMS related medication	Physiotherapy (x/week)	Psychotherapy (x/month)
1	Sham + MM	F	50	NSAID awr	0	1
2	Active + MM	F	70	Adalimumab Metamizole awr	1	0
3	Sham + MM	F	51	Trimipramine Novalgin awr CBD	1	0
4	Active + MM	F	68	Tilidine	2	1
5	No treatment	F	64	Trimipramine awr	2	0
6	Sham + MM	F	38	—	1	2
7	No treatment	F	56	—	1	0
8	Active + MM	F	57	—	0	2
9	Active + MM	F	68	Metamizole awr Diclofenac awr	0	0
10	No treatment	F	58	Celecoxib awr	1	0
11	No treatment	F	41	Duloxetine Opipramol	1-2	0
12	Sham + MM	F	58	Amitriptyline Mirtazapine	0	0
13	No treatment	F	45	Ramipril	2	0
14	Active + MM	F	68	—	0	0
15	Sham + MM	M	33	NSAID awr	0	0
16	No treatment	F	53	Novalgin awr	2	4
17	Sham + MM	M	59	Etoricoxib	1	0
18	Active + MM	F	55	NSAID awr	0	0
19	Active + MM	F	50	Paracetamol awr	0	0
20	Active + MM	F	47	NSAID awr Paracetamol awr	0	0
21	Active + MM	F	60	Amitriptyline	1	0
22	Sham + MM	F	49	NSAID awr	2	1
23	Sham + MM	F	48	—	0	0
24	Active + MM	F	54	Pregabalin	1	0
25	Sham + MM	F	55	NSAID awr Tilidine (by very strong pain)	1	2
26	Sham + MM	F	41	Novalgin awr	0	2
27	No treatment	F	64	—	0	0
28	No treatment	F	48	Etoricoxib awr Fluoxetine	1	0.5
29	No treatment	F	57	NSAID awr Pregabalin	0.5	1
30	No treatment	F	42	NSAID awr	0	0

F , female; M , male; awr , as and when required; NSAID , non-steroidal anti-inflammatory drugs; CBD , cannabidiol; — , none.